Using Multivalent Adenoviral Vectors for HIV Vaccination

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Gu, Linlin ^a   Li, Zan C ^a   Krendelchtchikov, Alexandre ^a   Krendelchtchikova, Valentina ^a   Wu, Hongju ^b   Matthews, Qiana L ^a,c  

^a University of Alabama at Birmingham   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EPITOPE; HISTIDINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; EMBRYO; GENETIC IMMUNIZATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; MOUSE; NONHUMAN; VIRION; VIRUS IMMUNITY; VIRUS PARTICLE;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; FEMALE; GENETIC VECTORS; HEK293 CELLS; HISTIDINE; HIV; HIV ANTIGENS; HIV INFECTIONS; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES;

MIRIDAE;

EID: 84875504792     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060347     Document Type: Article

References (33)

1. Crompton J, Toogood CI, Wallis N, Hay RT, (1994) Expression of a foreign epitope on the surface of the adenovirus hexon. JGenVirol 75 (Pt 1): 133-139.
2. McConnell MJ, Danthinne X, Imperiale MJ, (2006) Characterization of a permissive epitope insertion site in adenovirus hexon. JVirol 80: 5361-5370.
3. Worgall S, Krause A, Rivara M, Hee KK, Vintayen EV, et al. (2005) Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. JClinInvest 115: 1281-1289.
4. Matthews QL, Yang P, Wu Q, Belousova N, Rivera AA, et al. (2008) Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J 5: 98.
5. Matthews QL, Fatima A, Tang Y, Perry BA, Tsuruta Y, et al. (2010) HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One 5: e11815.
6. Abe S, Okuda K, Ura T, Kondo A, Yoshida A, et al. (2009) Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. JGene Med 11: 570-579.
7. Shiratsuchi T, Rai U, Krause A, Worgall S, Tsuji M, (2010) Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest 120: 3688-3701.
8. Palma C, Overstreet MG, Guedon JM, Hoiczyk E, Ward C, et al. (2011) Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice. Vaccine 29: 1683-1689.
9. Bayer W, Tenbusch M, Lietz R, Johrden L, Schimmer S, et al. (2010) Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection. J Virol 84: 1967-1976.
10. Matthews QL, (2011) Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Mol Pharm 8: 3-11.
11. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, et al. (2010) Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16: 319-323.
12. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, et al. (2007) Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13: 100-106.
13. Kong WP, Wu L, Wallstrom TC, Fischer W, Yang ZY, et al. (2009) Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 83: 2201-2215.
14. Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, et al. (2010) Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 5: e12873.
15. Kaufman DR, Li F, Cruz AN, Self SG, Barouch DH, (2012) Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys. Vaccine 30: 506-509.
16. Krause A, Joh JH, Hackett NR, Roelvink PW, Bruder JT, et al. (2006) Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. JVirol 80: 5523-5530.
17. Seregin SS, Hartman ZC, Appledorn DM, Godbehere S, Jiang H, et al. (2010) Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor. J Innate Immun 2: 353-359.
18. Seregin SS, Aldhamen YA, Appledorn DM, Hartman ZC, Schuldt NJ, et al. (2010) Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. Blood 116: 1669-1677.
19. Worgall S, Busch A, Rivara M, Bonnyay D, Leopold PL, et al. (2004) Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. JVirol 78: 2572-2580.
20. Worgall S, Krause A, Qiu J, Joh J, Hackett NR, et al. (2007) Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. JVirol 81: 13801-13808.
21. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, et al. (1994) Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS ResHumRetroviruses 10: 359-369.
22. Purtscher M, Trkola A, Grassauer A, Schulz PM, Klima A, et al. (1996) Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS 10: 587-593.
23. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, et al. (1994) A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS ResHumRetroviruses 10: 1651-1658.
24. Wu H, Han T, Belousova N, Krasnykh V, Kashentseva E, et al. (2005) Identification of sites in adenovirus hexon for foreign peptide incorporation. JVirol 79: 3382-3390.
25. Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, et al. (2002) Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. JVirol 76: 12775-12782.
26. Zwick MB, Jensen R, Church S, Wang M, Stiegler G, et al. (2005) Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 79: 1252-1261.
27. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67: 6642-6647.
28. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, et al. (2001) A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17: 1757-1765.
29. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 10892-10905.
30. Vigne E, Mahfouz I, Dedieu JF, Brie A, Perricaudet M, et al. (1999) RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. JVirol 73: 5156-5161.
31. Garau J, Gomez L, (2003) Pseudomonas aeruginosa pneumonia. CurrOpinInfectDis 16: 135-143.
32. Zhong T, Li X, Zhou Z, Li T, Tian X, et al. (2012) Characterization of malleability and immunological properties of human adenovirus type 3 hexon hypervariable region 1. Arch Virol 157: 1709-1718.
33. Tang Y, Le LP, Matthews QL, Han T, Wu H, et al. (2008) Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX. Virology 377: 391-400.